Translation of "Solid cancer" in German

The most commonly reported solid organ cancer was lung cancer (11 cases).

Solid cancer-cell lines were lysed within 24 h by CAPRI cells.

In contrast to solid tumors, disseminated cancer cells are able to circulate in the body of an individual.

This was confirmed by a dedicated comparative pharmacokinetic study in solid cancer patients with normal renal function (8 patients), moderate (8 patients) and severe (9 patients) renal impairment, who received several cycles of cabazitaxel in single IV infusion up to 25 mg/m2.

It is used in adults, adolescents and children to treat solid tumours (cancer) in various parts of the body that are caused by a change in the NTRK gene (neurotrophic tyrosine receptor kinase).

Overall, the safety profile of T/LAIV in a limited number of subjects with mildly to moderately nonHIV related compromised immune function, asymptomatic or mildly symptomatic HIV infection, or cancer (solid tumors and haematological malignancies) was comparable to that in healthy individuals and does not indicate any untoward effect.

The incidence rate did not increase for malignancies overall, by major type (non-melanomatous skin cancer, solid tumors, and hematologic malignancies), or for individual tumor types in the double blind and open label period compared to the double-blind experience.

Overall, the safety profile of T/LAIV in a limited number of subjects with mildly to moderately non- HIV related compromised immune function, asymptomatic or mildly symptomatic HIV infection, or cancer (solid tumors and haematological malignancies) was comparable to that in healthy individuals and does not indicate any untoward effect.

So powerful is its underground secret that it is capable of circulating diabetes, cure disease completely solid cancer in men (directly linked to poor diet and overweight factors), as well as the elimination of an entire spectrum of hazardous and other serious illnesses.

The key participation by DNA-PK in DNA repair processes and the evidence that the DNA-PK inhibitors allows mammal cells to become more radiation-sensitive enable therapeutic use of DNA-PK or DNA-PK/ATM or ATM-specific inhibitors as part of the treatment of, for example, solid cancer tumours by radiotherapy and/or chemotherapy aimed at DNA-DSBs.

It is mainly used as a precursor to epirubicin which is used as a cytostatic in chemotherapy of breast cancer, non-Hodgkin lymphoma, sarcoma, stomach carcinoma and other solid types of cancer.

The key participation by DNA-PK in DNA repair processes and the evidence that the DNA-PK inhibitors allows mammal cells to become more radiation-sensitive enable therapeutic use of the DNA-PK-specific inhibitors as part of the treatment of, for example, solid cancer tumours by radiotherapy and/or chemotherapy aimed at DNA-DSBs.

In contrast with the CAPRI cells, the cells that were only CD3-activated were not capable of destroying the solid cancer-cell lines enumerated above.

The key participation of ATM in DNA repair processes and the evidence that ATM kinase deficiency allows mammal cells to become more radiation sensitive enables therapeutic use of the ATM-specific inhibitors as part of the treatment of, for example, solid cancer tumours by irradiation therapy and/or chemo-therapy, preferably aimed at DNA double-strand damage.

In the last 40 years there was no significant progress concerning the therapy of solid tumours like cancer of the colon, lungs, breast and prostate in spite of immense expenditure.

The primary objective of the study is to evaluate the safety and tolerability of the ACTengine® approach, and specifically IMA202, in target-positive solid cancer patients.

In the product range are antibodies and kits for the most common solid tumours, e.g. cancer of the breast, lung, gastro-intestinal tract, ovary, prostate, liver and skin.

This is also valid for radiation-induced leukemia and solid cancers.

Entirely different is the latency distribution for solid cancers.

Neuroblastoma is one of the most common solid cancers in children.

This risk ratio (solid cancers/leukemia) will increase in the future follow-up.

We try to focus on solid cancers in early stages with existing surgical treatment options.

This included 33 patients with non-melanoma skin cancers, 28 with solid organ cancers, and 6 with hematologic malignancies (4 with lymphomas and 2 with myelodysplastic syndromes).

Therefore, the experts concluded that the calculated risk of leukaemia is far below the risk of solid cancers.

In table 3, risk estimates for leukemia and for the total fatal risk from solid cancers are listed which are mainly based on the epidemiological data from the atomic bomb survivors.

The new estimates yield for the considered exposure conditions a risk value for the total number of malignancies (leukemia -t· solid cancers) which is about a factor 2 - ƒ higher than the estimate of UNSCEAR ten years ago.

The data available up to now enable, therefore, no direct conclusion on the final lifetime risk of radiogenic solid cancers.

In figure 4 the cumulative number of excess cases of leukemia and solid cancers is given which has been observed among the atomic bomb survivors

The main reason for the higher new values is not the revised dosimetry but the application of a relative risk projection model for solid cancers assuming a constant relative excess risk with time after exposure.

An implication of the use of the multiplicative model is that for the majority of solid cancers it results in an increasing risk with time after exposure, following the natural increase with age.

Roche announced today that it has received European marketing approval for a simple and convenient once weekly subcutaneous injection of NeoRecormon (epoetin beta) 30,000 IU for the treatment of anaemia in patients with solid cancers receiving chemotherapy.